ALK B ALK-ABELLO A/S

Invitation to the presentation of ALK’s results for the first six months (Q2) 2024 on Friday 23 August 2024

Invitation to the presentation of ALK’s results for the first six months (Q2) 2024 on Friday 23 August 2024

ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its results for the first six months (Q2) 2024 in the morning of 23 August 2024.

Later same day, the company will host a presentation for investors and analysts at 1:30 p.m. CEST, where ALK’s management will comment on the results for the first six months and outlook and be available for questions.

ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR.

Live audio webcast

The meeting will be audio webcasted live and be available for replay on ALK’s website

Conference call

If you wish to participate via telephone, please register for the conference call by using this link: and follow the instructions. You will receive an email from with dial-in details, including a passcode and a pin code. Please make sure to whitelist  

and/or check your spam filter. We advise you to register on the day before the call at the latest.

Presentation

The presentation slides will be available on shortly before the meeting starts.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Maiken Riise Andersen, tel.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen. Find more information at

Attachment



EN
14/08/2024

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier o...

Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer ALK (ALKB:DC / OMX: ALK B / AKBLF): I henhold til artikel 19 i EU forordning nr. 596/2014 af 16. april 2014 om markedsmisbrug (markedsmisbrugsforordningen), følger hermed indberetning af ledende medarbejderes transaktioner som beskrevet i vedhæftede meddelelse. ALK-Abelló A/S For yderligere oplysninger kontakt venligst:Investor Relations: Per Plotnikof, tlf. 4574 7527, mobil 2261 2525Media: Maiken Riise Andersen, tlf. 5054 1434 Vedhæftet fil

August 27, 2024 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Report on transactions with ALK-Abelló A/S B-shares and associated sec...

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff ALK (ALKB:DC / OMX: ALK B / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff as set forth in the attached announcement. ALK-Abelló A/S For further information please contact:Investor Relations: Per Plotnikof, tel. , mobile Media: Maiken Riise Andersen, tel. Attachment

August 27, 2024 1 EN
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Morten Larsen
  • Peter Sehested
08/25/24 August 25, 2024 1 EN
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Morten Larsen
  • Peter Sehested
08/22/24 August 22, 2024 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Six-month interim report (Q2) 2024 - English version only

Six-month interim report (Q2) 2024 - English version only Company release No. 16/2024 ALK delivers 21% organic revenue growth with an operating profit margin of 19% in Q2 (unaudited) Revenue growth was driven by a continued strong momentum in tablet sales, and improved performance of injection- and drop-based allergy immunotherapy products. ALK’s European and International markets were key contributors to growth. The increase in operating profit (EBIT) of 189% is in-line with ALK’s financial targets. Full-year outlook has been upgraded. Q2 performance highlights Comparative figures...

August 22, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch